Southern Medical University Southern Hospital

Based at the Guangdong Provincial Institute of Nephrology, the Guangdong Provincial Key Clinical Specialty of Urology, and the State Key Laboratory of Organ Failure, two series of studies—a novel mechanism of BK polyomavirus pathogenesis and antibody-mediated rejection therapy in mouse transplantation—were published in top international journals in the field of organ transplantation. The institute has authored five Chinese guidelines for kidney transplantation. It has undertaken over 30 research projects, including those funded by the National Natural Science Foundation of China and the Guangdong Provincial Natural Science Foundation, and has received over 20 awards, including the Guangdong Provincial Science and Technology Award. As a regional organ transplant center in South China, it is one of the few centers in China capable of performing complex multi-organ cluster transplants.

1. Historical Origins and Spiritual Inheritance: The discipline originated in the 1970s, with its predecessor being the transplant team of the Southern Hospital of the First Military Medical University, one of the earliest teams in China to carry out organ transplantation. Adhering to the military doctors' tradition of "rigorous and intensive research, saving critically ill and terminally ill patients," the Department of Kidney Transplantation was established independently in the 1990s. Starting with simple kidney transplantation, it gradually expanded to multi-organ combined transplantation, such as liver and kidney, pancreas and kidney, forming the discipline's development direction of "professional organ transplantation, combined organ transplantation features, precision transplantation medicine, and holistic transplantation nursing." In 2003, it completed the first pancreas-kidney combined transplantation in Guangdong Province, and in the same year, it completed the world's 9th liver-pancreas-duodenal combined transplantation, setting a record for elderly liver and kidney combined transplantation in Asia. It is the birthplace of multi-organ combined transplantation in South China. The discipline relies on the national key clinical specialty system for organ transplantation, possesses national-level scientific research platforms related to organ transplantation, Guangdong Province's key clinical specialty for organ transplantation, has established a transplantation immunology laboratory, and undertakes national-level projects such as the National Natural Science Foundation of China.

1. Core Business Operation Efficiency: A leading hospital with full-scale qualifications for liver, kidney, pancreas, heart, lung, and small intestine transplants; a multidisciplinary team (MDT) integrated diagnosis and treatment system (transplant surgery, anesthesia, critical care, infectious diseases, immunology, and imaging); having completed over 5,000 organ transplants, ranking among the top in the country in both quantity and quality. Combined liver-kidney, combined pancreas-kidney, and combined liver-pancreas-duodenal transplants are its signature services, while transplants for family members and children are its medical specialties. The success rate of surgery and the long-term survival rate of transplanted organs have reached the world's advanced level, and the medical influence has radiated to the central and southern regions of China, Hong Kong, Macao and Taiwan, and Southeast Asian countries; the perioperative mortality rate and long-term survival rate of grafts have reached the international advanced level; and a complete chain system has been established for organ procurement and preparation, transplantation surgery, individualized management of immunosuppression, and long-term follow-up.

1. Discipline Positioning, Core Advantages, and National/Global Benchmarks: A regional organ transplant center in South China, and one of the few centers in China capable of performing complex multi-organ cluster transplants. Core Advantages: Multi-organ transplantation, transplant immune rejection mechanisms, BK virus-related transplant kidney disease, and transplantation for elderly/diabetic end-stage renal disease. Domestically, it benchmarks itself against the transplant centers of Tongji University, Sun Yat-sen University, and the First Affiliated Hospital of Zhejiang University; its basic research on complex multi-organ cluster transplantation and antibody-mediated rejection (AMR) has reached international standards, and it has spearheaded the development of domestic kidney transplantation treatment guidelines.

The Department of Hematology at Nanfang Hospital, Southern Medical University, was among the first batch of national key clinical specialties to pass inspection and is one of the largest hematology treatment and bone marrow transplantation centers in South China. The department's landmark academic contributions include precise stratified diagnosis and treatment of acute leukemia and breakthroughs in the source of hematopoietic stem cell transplant donors. Its comprehensive care and management model for hemophilia is a leading feature nationwide. For many consecutive years, it has consistently ranked among the top ten in the Fudan University's ranking of Chinese hospital specialty reputations and first in South China (ranking seventh nationwide in 2021 and 2023).

Historical Origins and Spiritual Inheritance:

The Department of Hematology at Nanfang Hospital was established in the 1970s, making it one of the earliest hematology specialties in China. It became authorized to grant master's degrees in 1993 and doctoral degrees in 1996. Subsequently, it was approved as a postdoctoral research station, a national key clinical specialty, a national clinical trial base for new drugs for hematological diseases, a national specialist physician training base, the Guangdong Provincial Hematological Disease Medical Quality Control Center, and the China Hemophilia Diagnosis and Treatment Training Center of the World Federation of Hemophilia. In 2011, the Southern Medical University Institute of Hematology was established.

Core business operational efficiency:

The department currently consists of a routine outpatient ward (102 beds), a hematopoietic stem cell transplantation ward (34 beds), the Huiqiao Building ward (16 beds), and a key laboratory for hematological diseases (500㎡). It has 140 medical, nursing, and technical staff, including 34 physicians (13 with senior professional titles, all holding master's degrees or above, and 13 with overseas study experience), 4 doctoral supervisors, and 5 master's supervisors. The department is at the leading and advanced level nationally in precision diagnosis and treatment of leukemia, targeted therapy for lymphoma/myeloma, hematopoietic stem cell transplantation and prevention and treatment of complications, and comprehensive care for hemophilia diagnosis and treatment.

Discipline Positioning and Benchmarking:

It is a National Key Clinical Specialty, a Key Specialty of Hematology in Guangdong Province, and the Guangdong Provincial Medical Quality Control Center for Hematology. Professor Liu Qifa currently serves as the Vice Chairman of the Hematology Branch of the Chinese Medical Association, the Head of the Infectious Diseases Group, a member of the Asia-Pacific Hematology Society, the Chairman of the Hematology Branch of the Guangdong Medical Association, and the Chief Expert of Hematologic Oncology in Guangdong Province. He was selected as a "National Outstanding Physician" in 2025. Since 2016, the discipline has consistently ranked among the top eight in the Fudan University Specialty Rankings nationwide and first in South China, ranking seventh nationwide in 2021 and 2023.

A national key clinical specialty, the only key hematology specialty in Guangdong Province, the Guangdong Provincial Hematology Medical Quality Control Center, and the largest transplant center and hematology treatment center in South China. It is a national drug clinical trial institution specializing in hematology (first batch certified in 1998), and the largest transplant center in South China, possessing a GMP-compliant cell production workshop. CAR-T clinical research relies on the department's mature technology platform, having established an independent intellectual property CAR-T platform and accumulated extensive clinical experience in the field of acute lymphoblastic leukemia. It is a benchmark center for CAR-T cell immunotherapy in South China and one of the first CAR-T clinical translation bases in China.

1. Historical Origins and Spiritual Inheritance

The Department of Hematology at Nanfang Hospital was founded in the 1970s and is one of the earliest hematology specialties in China. It was officially established in 1984, inheriting the military medical tradition of overcoming difficulties and studying medicine from the former Department of Hematology of the First Military Medical University. After 2010, it launched basic and clinical translational research on CAR-T. CAR-T cell therapy is the department's fourth core treatment pillar after hematopoietic stem cell transplantation and precision targeted therapy. Professor Liu Qifa, the discipline leader, has been practicing medicine for more than 40 years and has personally witnessed the entire process of Chinese hematology from the "desperate era" to the forefront of immunotherapy. His core spirit is condensed as "staying true to one's original aspiration and moving forward without stopping". It is one of the earliest centers in China to conduct CAR-T clinical trials, and has established an integrated CAR-T treatment unit for cell preparation, quality control, and clinical treatment. It is equipped with the Guangdong Provincial Clinical Medical Research Center for Hematologic Diseases and the National GCP New Drug Clinical Trial Platform of the Key Laboratory of Hematologic Diseases, and has the qualifications for clinical research on cell therapy.

1. Core Business Operation Efficiency

The center collaborates with the hematopoietic stem cell transplantation ward and the flow cytometry molecular diagnostic laboratory, and has established a dedicated CAR-T monitoring ward. It has built a comprehensive management system encompassing cell collection, in vitro preparation, reinfusion, CRS/ICANS complication monitoring, and long-term follow-up. The center undertakes Phase I/II/III clinical trials of multiple domestic/imported CAR-T, dual-target CAR-T, and universal CAR-T therapies. It has cumulatively completed numerous CAR-T treatments for relapsed/refractory B-cell hematologic malignancies, established standardized treatment procedures for CAR-T complications in South China, and spearheaded multi-center clinical trials. The department possesses an independent intellectual property CAR-T platform, and its DRGs level ranks first in Guangdong Province. The CAR-T and Lymphocytic Leukemia subspecialty is headed by Professor Zhou Hongsheng, who is the department's chief CAR-T expert.

1. Discipline Positioning, Core Advantages, and National/Global Benchmarking

The South China CAR-T Cell Immunotherapy Benchmark Center and one of the first CAR-T clinical translation bases in China. Ranked eighth nationally and first in the region in the Fudan University specialty rankings for five consecutive years, it currently ranks seventh nationally. Core strengths: CAR-T bridging haploidentical hematopoietic stem cell transplantation sequence protocols; standardized treatment of severe cases of CAR-T-related cytokine release syndrome (CRS)/immune effect cell-related neurotoxicity syndrome (ICANS); and clinical research on dual-target CAR-T new drugs. Domestically, it is comparable to Peking University People's Hospital and the Institute of Hematology and Blood Diseases of the Chinese Academy of Medical Sciences; the treatment plan for CAR-T combined with transplantation to treat relapsed and refractory leukemia has reached the international advanced level, and clinical data has been reported multiple times at the ASH and EHA international hematology conferences.

It is a National Key Clinical Specialty and a National Key Discipline (Department of Gastroenterology and Hepatology). Relying on the National Key Laboratory for Organ Failure Prevention and Treatment, the Key Laboratory of Infectious Disease Prevention and Control of South China (Ministry of Education), and the Guangdong Provincial Key Laboratory for Major Liver Disease Prevention and Control, it is the Guangdong Provincial Clinical Research Center for Viral Hepatitis and a National New Drug Clinical Trial Base. As the lead unit, it has continuously undertaken the National Science and Technology Major Projects during the 11th, 12th, and 13th Five-Year Plans. In the past three years, it has undertaken 3 projects under the 14th Five-Year Plan National Key R&D Program and 66 national and provincial-level projects, with a total funding of 80.97 million yuan. It has published 169 SCI papers in journals such as NEJM, Nature Medicine, J Hepatol, and Gut, with a total impact factor of 1711.5. It has been granted 14 invention patents, and its research results have generated 5.8 million yuan in commercialization. The research findings have been cited and recommended in domestic and international guidelines for the prevention and treatment of hepatitis B and liver cancer, and have won a total of 11 awards, including the National Science and Technology Progress Award, the Chinese Medical Science and Technology Award, and the Guangdong Provincial Science and Technology Progress Award.

1. Historical Origins and Spiritual Inheritance

Founded in 1951, the department was formerly the Department of Infectious Diseases of the First Military Medical University. It serves as a clinical and translational medicine platform for infectious diseases and liver diseases in South China. Professor Luo Kangxian (who, even at the age of 90, remains dedicated to the front line of hepatitis B prevention and treatment) is the team's role model, having received the second prize of the National Science and Technology Progress Award and the "China's Good Doctor - Outstanding Contribution Award." Inheriting the military doctors' academic spirit of "guarding the front line of infectious diseases and protecting liver disease patients," the department was renamed the Department of Infectious Diseases and Liver Disease Center in 2000. The core spirit is condensed into "Upholding Morality and Practicing Diligence, Pioneering and Innovating"—from SARS to COVID-19, the department has always been a pioneer in public health emergency treatment. In 2003, it achieved multiple "mosts" for a single department in Guangdong Province and the entire military, including the highest number of patients treated, the highest cure rate, the lowest mortality rate, and zero infections among medical staff. Relying on the National Key Laboratory for Organ Failure Prevention and Treatment, the Key Laboratory of Infectious Disease Prevention and Control of South China under the Ministry of Education, and the Key Laboratory for the Prevention and Control of Major Liver Diseases in Guangdong Province, it is the Guangdong Provincial Clinical Research Center for Viral Hepatitis and a National New Drug Clinical Trial Base.

1. Core Business Operation Efficiency

With 164 beds, the hospital is equipped with a liver center ward, a ward for complex infections (fever)/infectious diseases, and a liver tumor ward, as well as a negative pressure intensive care unit for infectious diseases. It sees over 120,000 outpatients and emergency patients annually and is a former chair unit of the Chinese Medical Association's Infectious Diseases Branch and the former president unit of the Asia-Pacific Society for the Study of the Liver. The hospital has established a multidisciplinary team (MDT) for liver diseases, covering the entire treatment chain for chronic liver diseases, liver failure, emerging infectious diseases, and complex unexplained fevers. It undertakes the treatment of major emerging infectious diseases and has established a national network for the prevention and control of mother-to-child transmission of hepatitis B.

1. Discipline Positioning, Core Advantages, and National/Global Benchmarking

A leading infectious disease department in South China, consistently ranking among the top 4 nationwide and number one in South China in Fudan University's specialty reputation rankings. Core strengths: comprehensive management of chronic hepatitis B, zero mother-to-child transmission of hepatitis B, non-invasive diagnosis of liver fibrosis, treatment of complex liver diseases and unexplained fever, and treatment of severe infections. Domestically, it is comparable to the Department of Infectious Diseases at the First Affiliated Hospital of Zhejiang University and Ditan Hospital; its clinical research on hepatitis B mother-to-child transmission prevention and new drugs for functional hepatitis B cure has reached international advanced levels, and its achievements have been cited by the WHO and Asia-Pacific guidelines for liver disease.

942273

A national key clinical specialty and a leading discipline in plastic, reconstructive, and repair surgery in South China; consistently ranking among the top in the Fudan University specialty rankings nationwide, and among the top hospitals in China in terms of scientific and technological achievements. It is a key discipline of the Ministry of Education, a doctoral degree-granting unit, and the Guangdong Provincial Medical Aesthetics Quality Control Center. It possesses the qualifications of the Chinese People's Liberation Army Burn and Plastic Surgery Center. In the past five years, it has received 22 National Natural Science Foundation of China grants, totaling 13.374 million RMB, and published 170 SCI papers, including in internationally authoritative journals such as Advanced Functional Materials (IF 19). It has received one second-class National Science and Technology Progress Award ("Development and Expansion Application of Subdermal Vascular Network Flap," the highest award in the domestic plastic and cosmetic surgery field), one first-class Guangdong Provincial Science and Technology Progress Award, and 16 provincial and ministerial-level awards. The hospital is at the forefront of hair transplantation and fat medicine in China, and has taken the lead in developing guidelines for the diagnosis and treatment of androgenetic alopecia in China.

1. Historical Origins and Spiritual Inheritance:

Founded in 1978, the department was originally the Department of Plastic Surgery of the First Military Medical University, making it one of the earliest established plastic surgery specialties in South China. It was approved to offer master's programs in 1989 and doctoral programs in 1998. In 2000, it became the PLA Burn and Plastic Surgery Center, and in 2014, it was selected as a National Key Clinical Specialty. It is also the affiliated unit of the Guangdong Provincial Plastic and Cosmetic Surgery Quality Control Center. Inheriting the academic spirit of "rigorous military medicine, repair-oriented, and aesthetically pleasing," the department initially focused on microscopic repair and reconstruction, gradually developing into a comprehensive plastic surgery discipline integrating trauma repair, organ reconstruction, cosmetic surgery, and regenerative medicine.

1. Core business operation efficiency:

The department operates as an integrated facility encompassing the main campus, Zengcheng branch, and a plastic and cosmetic surgery center. It boasts standardized wards, independent operating rooms, and a laser and regenerative medicine treatment platform. Currently, it has 6 senior-level professionals and 15 associate senior-level professionals, forming a pyramid-shaped talent structure. The department sees over 60,000 outpatients annually and performs over 10,000 surgeries annually, covering the entire chain of services including complex wound repair, congenital malformation correction, external organ reconstruction, cosmetic surgery, hair transplantation, and fat regeneration medicine. In 2023, the department opened a plastic and cosmetic surgery center with a total area of over 8,300 square meters, encompassing subspecialty centers such as hair medicine, fat medicine, breast augmentation, rhinoplasty, eye and craniofacial plastic surgery, laser cosmetology, and non-invasive injections.

1. Discipline Positioning, Core Advantages, and Benchmarking:

A national key clinical specialty and a leading department in plastic surgery, repair, and reconstructive surgery in South China; consistently ranking among the top in the Fudan University specialty rankings nationwide, and among the top in China's hospital science and technology rankings. Its core strengths include microsurgical flap repair, SVF-gel fat regeneration technology, hair transplantation, and late-stage facial paralysis repair; its anterolateral thigh flap technique is an international benchmark, widely used globally. Its overall strength is comparable to top domestic plastic surgery centers, and some regenerative repair techniques have reached international advanced levels. It has established national and provincial-level research platforms, undertaking multiple national-level projects including those funded by the National Natural Science Foundation of China, with achievements winning the second prize of the National Science and Technology Progress Award. In 2018, its comprehensive specialty ranking jumped to the top three nationwide and first in South China; in 2021, its hospital science and technology rankings ranked seventh nationwide.